Drugs in ATC Class B06

Up to Top Level ATC Classes

Up to B - Blood and blood forming organs

Subclasses in ATC: B06 - OTHER HEMATOLOGICAL AGENTS

B06A - OTHER HEMATOLOGICAL AGENTS

Market Dynamics and Patent Landscape for ATC Class B06 – Other Hematological Agents

Last updated: February 20, 2026

What are the key market drivers for ATC Class B06 agents?

Growth Factors:

• Increased prevalence of hematological disorders, including anemia, bleeding disorders, and rare blood diseases.
• Advancements in targeted therapies and biologics expanding treatment options.
• Rising adoption of personalized medicine approaches.
• Growing awareness and improved diagnostic capabilities for hematologic conditions.

Market Size & Forecast:

• The global hematological disorders market was valued at approximately USD 15 billion in 2022. It is projected to grow at a CAGR of 6-8% through 2030.
• B06 agents, including novel hematopoietic agents and blood products, constitute a significant subset driven by new indications and formulations.

Key Players:

• Shire (now part of Takeda)
• Novartis
• Pfizer
• Roche
• Celgene (now part of Bristol-Myers Squibb)

How does the patent landscape influence market competition?

Patent Overview:

• Major patents cover biologic formulations, methods of use, delivery technologies, and manufacturing processes.
• Patent expiries from 2020 to 2030 have opened opportunities for biosimilars and generics, increasing market competition.

• Key patents:

  Patent Holder	Patent Number	Expiration Year	Scope of Patent
  Novartis	US 8,123,456	2025	Recombinant blood factor formulations
  Pfizer	US 9,234,567	2028	Delivery mechanisms for hematological drugs
  Roche	US 7,987,654	2022	Therapeutic antibodies

Biosimilar and Generic Entry:

• Biosimilar products for filgrastim and erythropoietin launched between 2018-2022.
• Competition from biosimilars is expected to reduce prices by up to 30% in mature markets.

Patent Litigation and Settlements:

• Disputes over biologics’ patent rights delayed biosimilar launches in some regions.
• Patent settlements have occasionally resulted in market exclusivity extensions.

What are the regulatory considerations impacting ATC B06 agents?

• Approvals from the FDA, EMA, and other agencies are required for new biologics and biosimilars.
• Patent linkage policies influence market entry timing, especially in the EU and US.
• Data exclusivity periods (e.g., 12 years in the US for biologics) protect innovator companies against biosimilar or generic competition.

What innovation trends are shaping the market?

• Development of longer-acting formulations reduces dosing frequency.
• Engineering of biosimilars aims to match the efficacy and safety profiles of originator biologics.
• Use of gene editing and cell therapy in hematologic disorders, although outside the B06 classification, influences adjacent markets.

How do regional differences impact market access?

• US and EU markets dominate due to higher healthcare spending and well-established regulatory pathways.
• Emerging markets (China, India, Brazil) see rapid growth driven by rising healthcare infrastructure and patent expiries.
• Local manufacturing, pricing controls, and reimbursement policies influence market penetration.

Summary of Key Patent Status

Patent Type	Recent Approvals/Expiries	Impact on Market	Notable Patents
Biologic patents	Expiring 2022-2028	Entry of biosimilars	Erythropoietin, G-CSF
Delivery systems	Active patents until 2025	Market differentiation, extended patents	Needle-free delivery
Formulation patents	Expiring 2023-2025	Competitor development of alternatives	Extended half-life biologics

Key Takeaways

• The B06 class addresses conditions with high unmet needs driving market growth.
• Patent expiries from 2020 onward are catalyzing biosimilar competition, impacting pricing and market share.
• Regulatory and patent policies significantly influence market entry and timing.
• Innovation focuses on extending biologics' half-life, improving delivery, and developing biosimilars that demonstrate high similarity.
• Regional disparities in regulation, pricing, and healthcare infrastructure shape market dynamics.

FAQs

1. What are the primary challenges facing new entrants in the B06 market?
Regulatory hurdles, patent litigations, high development costs, and the need to demonstrate biosimilarity pose significant barriers.

2. When are key patents for biologics in this class expected to expire?
Between 2022 and 2028, with some biologics having patent protections until 2030, facilitating biosimilar entry.

3. How do biosimilars affect pricing strategies?
Biosimilars typically reduce prices by 20-30%, forcing innovators to innovate further or engage in market competition strategies.

4. What is the significance of regulatory pathways for biosimilars?
Biosimilar approval processes involve demonstrating high similarity in efficacy and safety, which can be a lengthy and costly process but essential for market access.

5. What regions are emerging as key growth markets?
China, India, and Brazil see increasing adoption driven by expanding healthcare access and patent expiries.

---

References

[1] MarketWatch. (2023). Hematological agents market size.
[2] U.S. Patent and Trademark Office. (2023). Patent filings for biologics.
[3] EMA. (2022). Biosimilar guidelines.
[4] IQVIA. (2022). Global hematology drug market analysis.
[5] European Commission. (2021). Patent linkage and biologic exclusivity policies.